Predict your next investment

V-Wave company logo
HEALTHCARE | Medical Devices & Equipment / Therapeutic Devices
vwavemedical.com

See what CB Insights has to offer

Founded Year

2009

Stage

Series C - II | Alive

Total Raised

$128M

Last Raised

$28M | 10 mos ago

About V-Wave

V Wave, founded in 2010, has developed a miniature valve which is implanted by catheterization into the left ventricle. This reduces the pressure on the muscle be controlling the blood flow between the heart chambers in patients who are frequently hospitalized with heart attacks. The valve is intended to reduce hospitalizations and improve patients' quality of life.

V-Wave Headquarter Location

5 Tarshish Street

Caesarea Business Park, 3088900,

Israel

+972 77 316 8550

Latest V-Wave News

Empagliflozin improves outcomes in HFrEF, regardless of baseline health status

Apr 16, 2021

Disclosures: Butler reports he received consultant fees from Boehringer Ingelheim, Cardior, CVRx, Foundry, G3 Pharma, Imbria, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, Sanofi, Sequana Medical, V-Wave Ltd and Vifor. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio The benefits of empagliflozin compared with placebo for HF with reduced ejection fraction occurred regardless of health status at baseline, according to a secondary analysis of the EMPEROR-Reduced trial. In addition, treatment with the SGLT2 inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) was associated with improved health-related quality of life outcomes that were sustained at 12 months. For this analysis researchers evaluated whether the benefits of empagliflozin varied by baseline health status and impacted patient-centered outcomes in HFrEF, as measured by KCCQ score. Data were derived from Butler J, et al. Eur Heart J. 2021;doi:10.1093/eurheartj/ehaa1007. As Healio previously reported , empagliflozin improved CV and renal outcomes in patients with HFrEF, regardless of diabetes status, according to findings from the EMPEROR-Reduced trial presented at the 2020 European Society of Cardiology Congress. Javed Butler “It is important to assess the benefit of novel therapies on clinically relevant endpoints across the spectrum of disease severity, as has been done previously with ACE inhibitors, beta-blockers and mineralocorticoid receptor antagonists in HFrEF,” Cardiology Today Editorial Board Member Javed Butler, MD, MPH, MBA, FACC, FAHA, professor and chairman of the department of medicine at the University of Mississippi Medical Center, and colleagues wrote. “Patients with more advanced disease may or may not respond similarly to those with milder symptoms and functional impairment.” For this analysis, published in the European Heart Journal, researchers evaluated whether the benefits of empagliflozin varied by baseline health status and impacted patient-centered outcomes in HFrEF, as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ). Clinical outcomes of empagliflozin Researchers reported that empagliflozin compared with placebo reduced the primary outcome of CV death or HF hospitalization regardless of baseline KCCQ clinical summary score (CSS) tertile: HR for KCCQ-CSS of less than 62.5 = 0.83; 95% CI, 0.68-1.02; HR for KCCQ-CSS of 62.6 to 85.4 = 0.74; 95% CI, 0.58-0.94; and HR for KCCQ-CSS of 85.4 or more = 0.61; 95% CI, 0.46-0.82; P for trend = .1. Results were similar for baseline KCCQ total symptom scores (TSS) and KCCQ overall summary scores (OSS). Health-related quality of life outcomes At 3, 8 and 12 months, empagliflozin improved KCCQ-CSS (by 1.94, 1.35 and 1.61 points, respectively), KCCQ-TSS (by 2.52, 1.64 and 1.69 points, respectively) and KCCQ-OSS (by 1.77, 1.3 and 1.52 points, respectively) compared with placebo, the researchers wrote. Butler and colleagues found that, at each time point, patients on empagliflozin were more likely to improve KCCQ-CSS and less likely to experience deterioration (P for all < .05). At 3 months, the likelihood of a 5-point or greater improvement (OR = 1.2; 95% CI, 1.05-1.37), a 10-point or greater improvement (OR = 1.26; 95% CI, 1.1-1.44) and a 15-point or greater improvement (OR = 1.29; 95% CI, 1.12-1.48) in KCCQ-CSS was higher for the empagliflozin group compared with placebo. The likelihood of a 5-point or greater deterioration was also lower for the empagliflozin group compared with placebo (OR = 0.75; 95% CI, 0.64-0.87; P for all < .05). At 8 and 12 months, the likelihood of improvement in KCCQ-CSS was higher for the empagliflozin group and the likelihood of deterioration was lower for the empagliflozin group compared with placebo (P for all < .05). “Empagliflozin significantly improved cardiovascular outcomes across the range of baseline KCCQ-23 domains and improved health status in patients with HFrEF,” the researchers wrote. “Treatment with empagliflozin was accompanied by a higher likelihood of improvement and a lower likelihood of deterioration in health status. The highly concordant findings on patient-reported health status in the EMPEROR-Reduced and DAPA-HF trials support a role for SGLT2 inhibitors as a part of foundational treatment of HFrEF.” Read more about

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing V-Wave

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

V-Wave is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

8,753 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

V-Wave Patents

V-Wave has filed 45 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiology
  • Cardiovascular physiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/5/2016

3/9/2021

Cardiac anatomy, Cardiac arrhythmia, Digestive system surgery, Vascular diseases, Digestive system procedures

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/5/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

3/9/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Cardiac anatomy, Cardiac arrhythmia, Digestive system surgery, Vascular diseases, Digestive system procedures

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

V-Wave Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

V-Wave Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.